Compare · CERS vs MMM
CERS vs MMM
Side-by-side comparison of Cerus Corporation (CERS) and 3M Company (MMM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CERS and MMM operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MMM is the larger of the two at $93.88B, about 250.6x CERS ($374.7M).
- Over the past year, CERS is up 21.6% and MMM is up 10.0% - CERS leads by 11.6 points.
- Both names hit the wire about 7 times in the past 4 weeks.
- MMM has more recent analyst coverage (25 ratings vs 4 for CERS).
- Company
- Cerus Corporation
- 3M Company
- Price
- -
- -
- Market cap
- $374.7M
- $93.88B
- 1M return
- -16.40%
- +10.41%
- 1Y return
- +21.57%
- +10.00%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 1997
- News (4w)
- 7
- 7
- Recent ratings
- 4
- 25
Cerus Corporation
Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation has collaboration with LifeSouth Community Blood Centers to manufacture INTERCEPT Fibrinogen Complex. The company was incorporated in 1991 and is headquartered in Concord, California.
3M Company
3M Company develops, manufactures, and markets various products worldwide. It operates through four business segments: Safety and Industrial, Transportation and Electronics, Health Care, and Consumer. The Safety and Industrial segment offers personal safety products, industrial adhesives and tapes, abrasives, closure and masking systems, electrical markets, automotive aftermarket, and roofing granules to industrial, electrical, and safety markets. The Transportation and Electronics provides electronics, such as display materials and systems, electronic materials solutions; automotive and aerospace, and commercial solutions; advanced materials; and transportation safety products to transportation and electronic original equipment manufacturer customers. The Health Care segment offers medical and surgical supplies, skin health and infection prevention products, oral care, separation and purification sciences, health information systems, drug delivery systems, and food safety products to healthcare industry. The Consumer segment provides home improvement, home care, and consumer health care products, as well as stationery and office supplies to various consumers. This segment is also involved in the retail auto care business. It offers its products through various e-commerce and traditional wholesalers, retailers, jobbers, distributors, and dealers, as well as directly to users. 3M Company has a strategic collaboration with Merry Maids in residential cleaning sector; and collaborations with The Infectious Disease Research Institute and Duke Human Vaccine Institute to create a vaccine candidate with potential to provide protection against multiple variants of SARS-CoV-2. The company was founded in 1902 and is headquartered in St. Paul, Minnesota.
Latest CERS
- Amendment: SEC Form SCHEDULE 13G/A filed by Cerus Corporation
- Cerus Corporation to Participate in the 17th Annual Craig-Hallum Alpha Select Conference
- SEC Form S-3 filed by Cerus Corporation
- SEC Form 10-Q filed by Cerus Corporation
- Cerus Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Cerus Corporation Announces Third Quarter 2026 Financial Results
- Cerus Corporation Announces Positive Topline Results from Phase 3 RedeS Trial of the INTERCEPT Blood System for Red Blood Cells
- Cerus Corporation to Release Third Quarter 2026 Financial Results on November 2, 2026
- Cerus Corporation Announces Workshop and Abstracts at the 2026 AABB Annual Meeting
- Chief Legal Officer Jensen Chrystal sold $89,529 worth of shares (30,000 units at $2.98) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 936,657 units (SEC Form 4)
Latest MMM
- 3M downgraded by Wolfe Research
- The Dow Rallies Back Above a Key Average, but Five Charts Made Even Bigger Moves Today
- 3M Reaches Broad Resolution of AFFF Personal Injury Litigation
- 3M Board Approves New $6 Billion Share Repurchase Authorization, Declares Quarterly Dividend
- Meguiar’s® Reveals Ford F-100 & Aston Martin GT3 in its 2026 SEMA Booth
- EVP Chief Strategy Officer Van Wyck Jonathan G. exercised 1,501 shares at a strike of $174.34 and covered exercise/tax liability with 460 shares, increasing direct ownership by 400% to 1,302 units (SEC Form 4)
- Meguiar’s® Unleashes a Trove of New 2027 Car Care Products: Continuing 125 Years of Innovation!
- 3M and AWS collaborate to advance optical connectivity innovation
- Outside Big Tech, Tuesday's Earnings Winners Jumped as Much as 11%
- SEC Form 10-Q filed by 3M Company